Diabetes Mellitus Type 2 Clinical Trial
Official title:
Measurement of Cytokines, Bloodflow and Erythema Index After Pressure and Shear- Force Loading in Patients With Diabetes Mellitus Type 2
1. The objective of this study is to acquire knowledge about the development of reactive
hyperaemia and inflammatory responses of the skin after shear- force and pressure
loading. We want to investigate if patients with diabetes type 2 will develop more skin
damage, because of a decreased microvascular function.
2. The second objective of this study is: to investigate if the cytokine production of the
skin is increased in patients with type 2 diabetes with a history of Charcot
osteoarthropathy in comparison with patients with neuropathy without a history of
Charcot osteoarthropathy.
The participant is asked to put his left arm on a support cushion. Then we mark an area of
2.5 cm x 3 cm with a permanent marker at the plantar aspect of the left fore-arm and the
adhesive side of a Sebutape is placed within this area for collection of IL-1α/ total
protein concentrations in a non- loaded situation (event 1) for two minutes. Second, we
measure the cutaneous blood cell flux within the borders of the marked area with a Laser
doppler. Finally, we measure the erythema index in this area with a colorimeter. Then we
place the shear- pad over the marked area we apply 9,8 Newton (N) pressure with 19 N shear-
force for half an hour. After this period a new Sebutape is placed for two minutes, followed
by cutaneous blood cell flux and the erythema index measurement within the borders of the
marked area. We repeat these measures after 15 minutes, 30 minutes, 45 minutes and 60
minutes, At the same time we performed the same experiment at the right arm, but instead of
loading this arm with shear- force and pressure, we apply only 9,8 N pressure at this arm.
The same measures with the sebutape, laser doppler and colorimeter are done before and after
loading of the skin. The measures are repeated at 15 minutes, 30 minutes, 45 minutes and 60
minutes.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | |
Est. primary completion date | January 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Group A: - Healthy volunteers - > 40 years Group B; - patients with Diabetes Mellitus type 2 (DM) without neuropathy - age > 40 years - Valk score < 4 Group C: - Patients with DM type 2 with neuropathy - age > 40 years - Valk score > 4 Group D - Patients with (pre)- existing Charcot Osteoarhtropathy - age > 40 years - Valk score > 4 Exclusion Criteria: - Trauma fore arms - Skin diseases (psoriasis, eczema) - NSAID use in last seven days - Bèta blocker use - Corticosteroids - Auto- immune diseases - Muscular dystrophy - Malignancy - Participant is unable to give informed consent - Peripheral artery disease (doppler eai <0.9) - Hab1c percentage last 3 months > 11% |
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Maastricht University Medical Center |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Increase in IL-1alpha/ total protein ratio | 0, 15, 30, 45, 60 minutes after intervention | No | |
Primary | Increase in Cutaneous blood cell flux | 0, 15, 30, 45, 60 minutes after intervention | No | |
Primary | Increase in erythema index | 0, 15, 30, 45, 60 minutes after intervention | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01267448 -
Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia
|
Phase 4 | |
Active, not recruiting |
NCT05330247 -
Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study
|
N/A | |
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
Terminated |
NCT02373865 -
Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT01741181 -
Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2
|
Phase 4 | |
Completed |
NCT01305434 -
Mulberry Leaf Extract and Blood Glucose Control in Diabetics
|
Phase 1/Phase 2 | |
Completed |
NCT01330121 -
Bridging the Gap by Transitional Care
|
N/A | |
Recruiting |
NCT00992797 -
Diabetes Intervention Trial With Vitamin D in Subjects of Nordic and Sub-Indian Ethnicity
|
Phase 2 | |
Completed |
NCT01580904 -
Impact of Pharmaceutical Care in Diabetics Patients
|
N/A | |
Active, not recruiting |
NCT00728403 -
Metabolic and Therapeutic Effects of American and Korean Red Ginseng in the Treatment of Type 2 Diabetes
|
Phase 2 | |
Completed |
NCT00763815 -
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
|
Phase 3 | |
Active, not recruiting |
NCT00529815 -
Continuous Glucose Monitoring in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT00517465 -
A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.
|
Phase 1 | |
Completed |
NCT00119041 -
Diabetes Telemedicine Consultation: A Systems Improvement Intervention
|
N/A | |
Withdrawn |
NCT00417716 -
Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema
|
Phase 3 | |
Withdrawn |
NCT00600236 -
HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population
|
Phase 3 | |
Active, not recruiting |
NCT05887635 -
Study of Duodenal Mucosal RF Vapor Ablation in Subjects With Type-2 Diabetes Mellitus
|
N/A | |
Completed |
NCT03903965 -
Comparison of Retinal Perfusion Between Diabetic and Non-diabetic Patients With OCT Angiography After Cataract Surgery.
|
||
Completed |
NCT02666924 -
Cooking Classes for Chinese Canadian Patients Living With Diabetes
|
N/A | |
Recruiting |
NCT02501850 -
The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)
|
Phase 4 |